Prostate cancer (PCa) metastasis to bone is lethal and there is no adequate animal model to study the mechanisms underlying the metastatic process. Here we report that receptor activator of NF-κB ligand (RANKL) expressed by PCa cells consistently induced colonization or metastasis to bone in animal models. RANK-mediated signaling established a premetastatic niche through a feed forward loop, involving the induction of RANKL and c-Met, but repression of androgen receptor (AR) expression and AR signaling pathways. Site-directed mutagenesis and transcription factor deletion/interference assays identified common transcription factor complexes (TFs), c-Myc/Max and AP4, as critical regulatory nodes. RANKL-RANK signaling activated a number of mast...
BACKGROUND: Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (o...
Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulat...
Introduction and Objective: While prostate cancer (PCa) is curable at early diagnosis, metastatic PC...
Prostate cancer metastases to bone are observed in around 80% of prostate cancer patients and repres...
International audienceProstate cancer metastases to bone are observed in around 80% of prostate canc...
BACKGROUND Metastases to bone are a frequent complication of human prostate cancer and result in th...
Abstract Prostate cancer (PCa) morbidity in the majority of patients is due to metastatic events, wh...
The osteolytic nature of bone metastasis results from a tumor-driven increased bone resorption. Bone...
The osteolytic nature of bone metastasis results from a tumor-driven increased bone resorption. Bone...
Primary and secondary bone tumors clearly deteriorate quality of life and the activity of daily livi...
Patients with advanced prostate cancer almost invariably develop osseous metastasis. Although many s...
Receptor activator of NF kappa B ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key r...
Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoproteger...
Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoproteger...
Acting through its cognate receptor, receptor activator of nuclear factor-κB (RANK), RANK ligand (RA...
BACKGROUND: Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (o...
Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulat...
Introduction and Objective: While prostate cancer (PCa) is curable at early diagnosis, metastatic PC...
Prostate cancer metastases to bone are observed in around 80% of prostate cancer patients and repres...
International audienceProstate cancer metastases to bone are observed in around 80% of prostate canc...
BACKGROUND Metastases to bone are a frequent complication of human prostate cancer and result in th...
Abstract Prostate cancer (PCa) morbidity in the majority of patients is due to metastatic events, wh...
The osteolytic nature of bone metastasis results from a tumor-driven increased bone resorption. Bone...
The osteolytic nature of bone metastasis results from a tumor-driven increased bone resorption. Bone...
Primary and secondary bone tumors clearly deteriorate quality of life and the activity of daily livi...
Patients with advanced prostate cancer almost invariably develop osseous metastasis. Although many s...
Receptor activator of NF kappa B ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key r...
Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoproteger...
Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoproteger...
Acting through its cognate receptor, receptor activator of nuclear factor-κB (RANK), RANK ligand (RA...
BACKGROUND: Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (o...
Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulat...
Introduction and Objective: While prostate cancer (PCa) is curable at early diagnosis, metastatic PC...